Skip to main content
Premium Trial:

Request an Annual Quote

France's Cytoo Raises $4.7M to Grow High-Content Cell Analysis Business

NEW YORK (GenomeWeb News) – French high-content screening shop Cytoo said today that it has raised $4.7 million in a second funding round.

Cytoo, based in Grenoble, said that it will use the proceeds to grow its business internationally, and to expand its team and R&D efforts around its high-content cell-based screening tools for the life science research market.

New investor Auriga Partners led the financing, while existing investor Jacques Lewiner, the company's co-founder and supervisory board president, also participated.

Cytoo's flagship product, called Cytoochips, are 4 cm2 glass coverslips containing more than 20,000 adhesive micropatterns for individual cells. The chips are available in a wide range of geometries and are used to normalize cell morphology and behavior and control cell organization for more reliable analysis, the company said.

In May, Cytoo said that it had taken an exclusive, worldwide license to a patent portfolio for adhesive micropattern technology from Institut Curie and France's Centre National de la Recherche Scientifique.

Cytoo has also licensed patents from the French Atomic Energy Commission's Life Sciences Division and Harvard University, allowing the company freedom to operate.

In Sept. 2008, CEA Investissement, a subsidiary of the French Atomic Energy Commission, led a €1 million (about $1.46 million at the time) seed funding round in Cytoo, which the company used to launch the Cytoochips platform.

Filed under

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.